Dr. Martin Bultmann is a pharmacist by training and engineer by heart. He studied Pharmacy at the University of Bonn and finished his doctoral thesis "Knowledge based development of tablets out of granules" at the University of Heidelberg. After his thesis he decided to stay "a little longer" (yes, it turned out to be eight additional years) to continue beloved teaching and research on solid dosage forms - namely Roller Compaction, Knowledge based systems and Neural Nets, before he switched over to the Pharmaceutical Industry. Due to his various well-established contacts, he decided to take the role of section head for solid dosage form development at former Abbott in Ludwigshafen. In 2013 Abbott split into two companies and Dr. Bultmann stayed with the research and development focused part of the company, which assumed the name AbbVie. In the same year he became the head of the "Parenteral Pilot Plants" that manufactured all the supplies for the clinical trials under GMP. In 2017 Martin Bultmann got the opportunity to concentrate on the machine specific aspects of the fill finish process and became the head of the Ludwigshafen Process Engineering Sciences group for New Biological Entities (NBEs). Besides his passion for process improvements, lean manufacturing, simplification and development of novel, mainly first principle based in silico modelling approaches, he also became a highly recognized expert for troubleshooting of fill finish processes.
Despite all the industrial work, he never lost his dedication for teaching and as highly sought after speaker he was and still is giving guest seminars and workshops at various national and international Universities and meanwhile resumed lecturing at the University of Heidelberg on a continuous basis. In 2024 he founded the Institute for Pharmaceutical Process Development to offer Education on Pharmaceutical Process Development to the upcoming generation of students.
Martin is also the author of several Pharmaceutical Textbooks (Terminology, Basics of Drug Product Manufacturing, Maths and Statistics), is a research fellow of the AbbVie Community of Science's Volwiler Society, and member of several pharmaceutical societies.
Dr. Martin Bultmann receiving the Hershko International Biochemistry Award from Dr. Florian Kongoli at FLOGEN SIPS 2024
Dr. Florian Kongoli congratulating Dr. Martin Bultmann during the FLOGEN SIPS 2024 award ceremony
Dr. Martin Bultmann delivering an acceptance speech during the FLOGEN SIPS 2024 award ceremony
Dr. Martin Bultman Winner of the Hershko International Biochemistry Award.
Dr. Martin Bultmann is a pharmacist by training and engineer by heart. He studied Pharmacy at the University of Bonn and finished his doctoral thesis "Knowledge based development of tablets out of granules" at the University of Heidelberg. After his thesis he decided to stay "a little longer" (yes, it turned out to be eight additional years) to continue beloved teaching and research on solid dosage forms - namely Roller Compaction, Knowledge based systems and Neural Nets, before he switched over to the Pharmaceutical Industry. Due to his various well-established contacts, he decided to take the role of section head for solid dosage form development at former Abbott in Ludwigshafen. In 2013 Abbott split into two companies and Dr. Bultmann stayed with the research and development focused part of the company, which assumed the name AbbVie. In the same year he became the head of the "Parenteral Pilot Plants" that manufactured all the supplies for the clinical trials under GMP. In 2017 Martin Bultmann got the opportunity to concentrate on the machine specific aspects of the fill finish process and became the head of the Ludwigshafen Process Engineering Sciences group for New Biological Entities (NBEs). Besides his passion for process improvements, lean manufacturing, simplification and development of novel, mainly first principle based in silico modelling approaches, he also became a highly recognized expert for troubleshooting of fill finish processes.
